Top Management Presentation Financial Results for 2Q Fiscal 2012 (April 1 - September 30, 2012)

from the beginning

• Top Management Presentation Financial Results for 2Q Fiscal 2012 (April 1 - September 30, 2012)

• Key Message for 2nd Half FY2012

• Financial Overview

presenter :

Joji Nakayama
President and CEO

• Overview of FY2012 2Q Results- compared with FY2011 2Q results -(1)

• Overview of FY2012 2Q Results- compared with FY2011 2Q results -(2)

• Overview of FY2012 2Q Results- compared with FY2011 2Q results -(3)

• Overview of FY2012 2Q Results- compared with FY2011 2Q results -(4)

• Business Highlights

• Highlights Japan(1)

• Highlights Japan(2)

• Highlights North America & Europe

• Sales of Major Products

• Highlights Ranbaxy

• Highlights Next Mainstays(1)

• Highlights Next Mainstays(2)

• Future Schedule

• Global Research & Development

presenter :

Glenn Gormley MD PhD
Global Head of R&D
Senior Executive Officer

• Major R&D Pipeline

• Edoxaban (DU-176b) : Once Daily Oral Factor Xa Inhibitor

• Edoxaban (DU-176b) : Competitive advantage

• Prasugrel (CS-747) : Anti-platelet agent

• Prasugrel ACS-PCI Phase 3 in Japan PRASFIT - ACS

• Tivantinib (ARQ 197) : Oral Met inhibitor

• Denosumab (AMG 162) : Anti- RANKL Antibody

Denosumab: DIRECT Study Incidence of New or Worsening vertebral fractures

• Denosumab: DIRECT Study Lumbar Spine BMD Levels

• Denosumab: DIRECT Study Summary of Adverse Events

＠

Part I Q&A

• Q&A1

• Q&A2

• Q&A3

• Q&A4

• Q&A5

• Q&A6

Part II Q&A

• Q&A1

• Q&A2

• Q&A3

• Q&A4